Fundamental Analysis of CORMEDIX INC(NASDAQ:CRMD) stock

Fundamental Rating

Overall CRMD gets a fundamental rating of 3 out of 10. We evaluated CRMD against 198 industry peers in the Pharmaceuticals industry. While CRMD has a great health rating, there are worries on its profitability. CRMD has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRMD has reported negative net income.

CRMD had a negative operating cash flow in the past year.

In the past 5 years CRMD always reported negative net income.

In the past 5 years CRMD always reported negative operating cash flow.

1.2 Ratios

CRMD's Return On Assets of -56.46% is in line compared to the rest of the industry. CRMD outperforms 40.51% of its industry peers.

CRMD has a Return On Equity (-66.06%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-56.46%
ROE	-66.06%
ROIC	N/A

ROA(3y)-48.42%

ROA(5y)-67.53%

ROE(3y)-54.98%

ROE(5y)-79.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRMD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CRMD has more shares outstanding

Compared to 5 years ago, CRMD has more shares outstanding

There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CRMD has an Altman-Z score of 8.40. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of CRMD (8.40) is better than 84.10% of its industry peers.

There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	8.4

ROIC/WACCN/A

WACC9.22%

2.3 Liquidity

CRMD has a Current Ratio of 6.97. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.

CRMD has a better Current ratio (6.97) than 77.95% of its industry peers.

CRMD has a Quick Ratio of 6.78. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 6.78, CRMD is doing good in the industry, outperforming 78.46% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.97
Quick Ratio	6.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CRMD have decreased strongly by -24.32% in the last year.

The Revenue for CRMD has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-24.32%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-30%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

CRMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.00% yearly.

Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 280.99% on average per year.

EPS Next Y17.82%

EPS Next 2Y37.65%

EPS Next 3Y48.5%

EPS Next 5Y30%

Revenue Next Year10163.5%

Revenue Next 2Y1715.77%

Revenue Next 3Y766.19%

Revenue Next 5Y280.99%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRMD. In the last year negative earnings were reported.

Also next year CRMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CRMD's earnings are expected to grow with 48.50% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.65%

EPS Next 3Y48.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CRMD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CORMEDIX INC

NASDAQ:CRMD (5/3/2024, 7:00:01 PM)

After market: 5.83 -0.01 (-0.17%)

5.84

+0.47 (+8.75%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap321.08M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-56.46%
ROE	-66.06%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.97
Quick Ratio	6.78
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-24.32%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y17.82%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CORMEDIX INC (CRMD)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens